Recherchiere Firmenbekanntmachungen und finanzielle Kennzahlen
EU-Förderung (10,5 Mio. €): Biomarker bei atopischer Dermatitis und Psoriasis Hor01.04.2019 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Auf einen Blick
Text
Biomarker bei atopischer Dermatitis und Psoriasis
Our objective is to provide a taxonomic and predictive systems medicine model of Atopic Dermatitis and Psoriasis based on clinical and molecular profiling to (i) identify determinants of clinically relevant outcomes (disease manifestation, progression, comorbidity development and treatment response) (ii) improve understanding on shared and distinct disease mechanism(s) and associated signatures, and their relative importance in patient subpopulations and (iii) deliver biomarkers that identify disease trajectories and treatment response for use in drug development and clinical practice. BIOMAP will create a biospecimen and data resource of unprecedented scale and depth, accessible via a central data and analysis portal, harmonizing diverse, high quality, multi-dimensional datasets on skin and blood (whole and single cell), large scale population-based and trial data; parallel clinical research infrastructure will deliver supplementary material flexible to the needs of the consortium. This resource will be systematically analyzed using state-of-the-art methodologies in epidemiology, molecular profiling, skin biology and mathematical modelling to define disease and drug endotypes and how these interact with lifestyle and environmental factors. Selected, highly discriminatory, associated biomarkers will pass through a diagnostics pipeline (novel in-silico trial methods and assay development), ready for immediate translation. BIOMAP is expected to drive drug discovery to target causal mechanisms, shorten drug development pathways, and fundamentally change the diagnosis and management paradigm, from re-active to pro-active strategies that encompass disease biology and life-time trajectory, matching the intervention (prevention, modification of risk factors, therapeutics) with endotypes. Clinically annotated endotypes and associated biomarkers will identify when, in whom and how to intervene to minimize disease impact and improve outcomes.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| AIT Austrian Institute OF Technology GmbH | 466.711 € |
| Academisch Ziekenhuis Leiden | 410.938 € |
| Almirall SA | 0,00 € |
| 0,00 € | |
| CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS | 81.250 € |
| CHRISTIAN-ALBRECHTS-UNIVERSITAET ZU KIEL | 1.478.387 € |
| 544.119 € | |
| EURICE EUROPEAN RESEARCH AND PROJECT OFFICE GmbH | 666.685 € |
| HAHN-SCHICKARD-GESELLSCHAFT für ANGEWANDTE FORSCHUNG e. V. | 149.625 € |
| HEINRICH-HEINE-UNIVERSITAET DUESSELDORF | 221.625 € |
| ITA-SUOMEN YLIOPISTO | 175.125 € |
| Information Technology FOR Translational Medicine (Ittm) SA | 460.360 € |
| 28.530 € | |
| Karolinska Institutet | 599.033 € |
| King's College London | 1.573.555 € |
| Kobenhavns Universitet | 274.500 € |
| 0,00 € | |
| 182.957 € | |
| NOVARTIS PHARMA AG | 0,00 € |
| Pfizer Ltd. | 0,00 € |
| SANOFI-AVENTIS DEUTSCHLAND GmbH | 0,00 € |
| Stichting Amsterdam UMC | 161.875 € |
| Stichting Radboud Universitair Medisch Centrum | 258.500 € |
| 0,00 € | |
| 415.801 € | |
| TECHNISCHE UNIVERSITAET MUENCHEN | 185.000 € |
| 0,00 € | |
| Tartu Ulikool | 193.500 € |
| The University of Edinburgh | 103.380 € |
| UCB Biopharma | 0,00 € |
| UNIVERSITAETSKLINIKUM FREIBURG | 347.720 € |
| UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF | 63.125 € |
| Universitat Wien | 208.350 € |
| Universite DU Luxembourg | 488.936 € |
| 746.636 € | |
| University of Dundee | 13.777,61 € |
Quelle: https://cordis.europa.eu/project/id/821511
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.
Die Visualisierungen zu "AIT Austrian Institute OF Technology GmbH - EU-Förderung (10,5 Mio. €): Biomarker bei atopischer Dermatitis und Psoriasis"
werden von
North Data
zur Weiterverwendung unter einer
Creative Commons Lizenz
zur Verfügung gestellt.
